Posted by Michael Rae on November 24, 2011 | Chief Science Officer's Team

Parkinson's disease is characterised by the loss of dopaminergic neurons from the substantia nigra, and cell therapy is being actively pursued as a means to replace the losses. Most trials to date have used fetal tissue, an approach that although transiently effective is unscalable and prone to immune rejection. Human dopaminergic neurons differentiated from stem cells have historically had poor therapeutic efficiency, but a new study using an improved differentiation protocol has shown much more positive results.

Posted by Daniel Kimbel on November 14, 2011 | SRF Education

At some point in the next few weeks, the Academic Initiative's section of sens.org will begin to look dramatically different, as our subsite undergoes its first-ever major revision. The planning for this website is complete, as is the Initiative's new logo, which the site will display.

Posted by Michael Rae on November 6, 2011 | Chief Science Officer's Team

"Senescent" cells progressively restrict the body's capacity for tissue renewal and secrete factors that disrupt local tissue homeostasis. A new study provides proof-of-concept that ablation of these cells can delay - and potentially contribute to the reversal of - age-related tissue dysfunction and disease.